8-K/A: Absci Q2 2025: Strong Execution, Extended Runway

Absci reports Q2 2025 financial results, highlights expanded Almirall collaboration, pipeline progress, and extended cash runway into H1 2028.

Summary

• Revenue for the second quarter ended June 30, 2025, was $0.6 million, a decrease from $1.3 million for the same period in 2024.
• Net loss for Q2 2025 was $30.6 million, compared to $24.8 million for Q2 2024.
• Research and development expenses increased to $20.5 million in Q2 2025 from $15.3 million in Q2 2024, primarily due to advancement of internal programs.
• Selling, general, and administrative expenses decreased to $8.5 million in Q2 2025 from $9.3 million in Q2 2024.
• Cash, cash equivalents, and short-term investments were $117.5 million as of June 30, 2025.
• In July 2025, Absci raised approximately $64 million in gross proceeds through an underwritten public offering ($50 million) and its at-the-market facility ($14 million).
• The company's existing cash, cash equivalents, and short-term investments are now believed to be sufficient to fund operations into the first half of 2028.
• The collaboration with Almirall was expanded with the election of a second target focused on dermatological indications, with potential milestone payments up to approximately $650 million across two programs.
• ABS-101 (anti-TL1A) Phase 1 interim data readout is anticipated in the second half of 2025.
• ABS-201 (anti-PRLR) is on track to enter a Phase 1/2a clinical trial in early 2026, with potential for an interim efficacy readout in the second half of 2026.
• Progress continues on ABS-301 (immuno-oncology) and ABS-501 (anti-HER2) preclinical programs.
• Absci anticipates signing one or more new partnerships in 2025, including with a Large Pharma company.

Sentiment

Score: 7

Explanation: While financial results for the quarter show increased losses and decreased revenue, the significant capital raise extending the cash runway, the expansion of a key collaboration with Almirall, and the continued strong progress across multiple internal AI-designed pipeline assets (ABS-101, ABS-201, ABS-301, ABS-501) indicate strong operational execution and future potential. The negative financial metrics are largely offset by strategic advancements and improved financial stability for future development.

Positives

• Cash runway extended into the first half of 2028 due to a successful capital raise of approximately $64 million in July 2025.
• Expanded collaboration with Almirall, adding a second target and potential for up to $650 million in upfront fees, R&D, and post-approval milestone payments.
• Successful delivery of AI de novo designed functional antibodies against a difficult-to-drug target for the first Almirall program.
• ABS-101 (anti-TL1A) Phase 1 interim data is expected in 2H 2025, with preclinical data supporting a superior immunogenicity profile and extended half-life.
• ABS-201 (anti-PRLR) shows potential as a best-in-class therapy for androgenetic alopecia, demonstrating high affinity, potency, extended half-life, and favorable developability.
• ABS-301 (immuno-oncology) has shown a potent anti-tumor response in in vivo target validation studies and broad potential in squamous cell carcinomas.
• ABS-501 (anti-HER2) AI-designed antibodies exhibit enhanced ADCC activity and suppress growth of trastuzumab-resistant xenograft tumors.
• Strategic collaboration with AMD is progressing, supported by a $20 million equity investment from AMD in January 2025.
• Anticipates signing one or more new partnerships in 2025, including with a Large Pharma company, indicating strong interest in their AI platform.

Negatives

• Revenue decreased to $0.6 million in Q2 2025 from $1.3 million in Q2 2024.
• Net loss increased to $30.6 million in Q2 2025 from $24.8 million in Q2 2024.
• Research and development expenses increased to $20.5 million in Q2 2025 from $15.3 million in Q2 2024, primarily driven by advancement of internal programs.
• Cash, cash equivalents, and short-term investments decreased to $117.5 million as of June 30, 2025, from $134.0 million as of March 31, 2025, prior to the July capital raise.

Risks

• Obtaining and maintaining necessary approvals from the FDA and other regulatory authorities.
• Replicating promising or positive results observed in preclinical studies in clinical trials.
• Dependence on third parties to support internal asset programs, including for the manufacture and supply of preclinical and clinical supplies.
• Ability to effectively collaborate on research, drug discovery, and development activities with partners or potential partners.
• Existing and potential partners' ability and willingness to pursue the development and commercialization of programs or product candidates under partnership agreements.
• Overall market conditions and regulatory developments that may affect activities under agreements.
• Uncertainty regarding the success of partnerships.
• Uncertainty regarding the gross use of cash, cash equivalents, and short-term investments, including revised guidance.
• Uncertainty regarding projected cash usage, needs, and runway.
• Uncertainty regarding the signing and number of additional partners and programs included in such partnerships.
• Uncertainty regarding technology development efforts and the application of those efforts.
• Uncertainty regarding the ability to execute with partners to create differentiated antibody therapeutic candidates in an efficient manner.
• Uncertainty regarding the ability to create and execute a successful development and commercialization strategy related to such candidates.
• Uncertainty regarding the ability to design and develop differentiated therapeutics to treat disease with unmet need.
• Uncertainty regarding the ability to market platform technologies to potential partners.
• Uncertainty regarding internal asset programs, including clinical development strategy, progress, and timing for various stages of development.
• Uncertainty regarding the generation and disclosure of data related to programs.
• Uncertainty regarding the translation of preclinical results and data into product candidates.
• Uncertainty regarding the significance of preclinical results, including in comparison to competitor molecules and in leading to differentiated clinical efficacy or product profiles.

Future Outlook

Absci anticipates signing one or more new partnerships, including with a Large Pharma company, in 2025. The company expects Phase 1 interim data for ABS-101 in the second half of 2025 and anticipates initiating a Phase 1/2a clinical trial for ABS-201 in early 2026, with potential for an interim efficacy readout in the second half of 2026. Cash, cash equivalents, and short-term investments are now believed to be sufficient to fund operations into the first half of 2028.

Management Comments

• "The past few months have been a period of strong execution for Absci, and we are positioned to build on this momentum." Sean McClain, Founder and CEO.
• "ABS-101 is advancing through clinical trials, ABS-201 is on track to enter the clinic early next year, and we recently announced a key milestone in our collaboration with Almirall." Sean McClain, Founder and CEO.
• "With a strengthened balance sheet and runway into the first half of 2028, we are well positioned to deliver on our mission." Sean McClain, Founder and CEO.
• "Post-Enhertu is really where the action is right now in the field. I think the first company that comes up with something that has significant benefit in Enhertu progressive disease is going to win." KOL (quoted in presentation).

Industry Context

Absci operates in the rapidly evolving biopharmaceutical sector, leveraging generative AI for drug discovery, a trend gaining significant traction. The company's focus on difficult-to-drug targets and unmet medical needs, such as androgenetic alopecia and specific oncology indications, positions it within high-growth segments. Its collaboration with AMD highlights the increasing convergence of AI/tech and biotech, aiming to scale drug creation platforms. The expansion of the Almirall partnership underscores the industry's growing adoption of AI-driven drug discovery platforms by established pharmaceutical companies.

Comparison to Industry Standards

• ABS-101 (anti-TL1A) is designed to achieve superior therapeutic properties and differentiation over first-generation clinical competitors like Merck's MK-7240, Roche's RVT-3101, and Sanofi/Teva's TEV-48574, specifically aiming for higher affinity/potency, binding to both monomer and trimer TL1A, low immunogenicity potential, high bioavailability, and convenient Q8W-Q12W subcutaneous dosing.
• ABS-201 (anti-PRLR) aims to unlock a new category of therapy for hair regrowth, addressing a significant unmet clinical need for androgenetic alopecia, with potential to be first to market in the U.S. It shows superior efficacy versus 5% topical minoxidil in a hair regrowth model and a >3x extended half-life in NHPs compared to HMI-115, suggesting potential for less frequent dosing (Q8W-Q12W vs. Q2W/Q4W for HMI-115).
• ABS-501 (anti-HER2) AI-designed antibodies demonstrate measurable enhancement of ADCC activity compared to trastuzumab and suppress growth of trastuzumab-resistant HER2+ breast tumors (e.g., JIMT-1), addressing unmet needs in later-line treatment regimens post-Enhertu.
• Absci's de novo AI design platform has successfully addressed difficult-to-drug target epitopes, such as the HIV Caldera region, where no natural or synthetic antibody previously existed, demonstrating a capability beyond traditional methods.

Stakeholder Impact

• Shareholders: Dilution from the public offering, but extended cash runway reduces immediate financing risk. Potential for future value creation from pipeline advancements and partnerships.
• Employees: Continued investment in R&D and platform improvements suggests stable or growing employment opportunities, particularly in AI and drug creation.
• Customers/Partners: Expanded collaboration with Almirall and anticipated new partnerships indicate growing trust and utility of Absci's AI platform.
• Creditors: Strengthened balance sheet and extended cash runway improve creditworthiness.

Next Steps

• Phase 1 interim data readout for ABS-101 anticipated in the second half of 2025.
• Initiation of a Phase 1/2a clinical trial for ABS-201 anticipated in early 2026.
• Potential for an interim efficacy readout for ABS-201 in the second half of 2026.
• Anticipate signing one or more new partnerships in 2025, including with a Large Pharma company.
• Continued preclinical development and further exploration of ABS-301's therapeutic potential.
• Continued advancement of internal pipeline programs and current/future partnered programs.
• Achieving ongoing platform improvements and operational efficiencies.
• ABS-101 Phase 1b/2a Study initiation anticipated 1H 2026.
• For the HIV-Caldera program, binders from this study will be selected for affinity maturation.
• Structure of de novo binder and epitope specificity for HIV-Caldera will be experimentally solved to confirm fidelity with designed structure and targeted epitope.

Key Dates

Recommendation

While the company reported increased net losses and decreased revenue for the quarter, these are common for clinical-stage biopharmaceutical companies heavily investing in R&D. The successful capital raise significantly extends the cash runway into H1 2028, de-risking near-term financing needs. The expansion of the Almirall collaboration and the strong preclinical and early clinical progress across multiple internal AI-designed assets (ABS-101, ABS-201, ABS-301, ABS-501) demonstrate significant scientific and strategic momentum. The anticipated new partnerships, especially with a Large Pharma, could provide further validation and non-dilutive funding. The stock is a 'hold' as the company is executing on its pipeline and extending its financial viability, but it remains a high-risk, high-reward investment given its clinical stage and reliance on future trial success and partnerships.

Keywords

Biopharmaceutical, Generative AI, Drug Discovery, Antibody Therapeutics, Clinical Stage, Inflammatory Bowel Disease, Androgenetic Alopecia, Immuno-oncology, HER2, AI Drug Creation Platform, SEC Filing, Financial Results, Biotech, Pharmaceutical, TL1A, PRLR, AMD, Almirall